Triptans for Acute Migraine: A Clinical Deep Dive

Generated November 2026 · Clinical Deep Dive0 CommentsThe joint guideline from the International Headache Society (IHS) and the Italian Society for the Study of Headaches (SISC) suggests triptans as first-line treatment for severe, disabling migraine attacks and as second-line treatment for milder attacks when over-the-counter analgesics fail. Cephalalgia The American College of Physicians (ACP) strongly recommends adding a triptan to a nonsteroidal anti-inflammatory drug (NSAID) to treat moderate to severe acute episodic migraine in outpatient settings for nonpregnant adults who do not respond adequately to an NSAID. Ann Intern Med Yet in a Danish nationwide register study, an estimated 12.3% of people with migraine bought a triptan between 2014 and 2019, and about 43% of first-time buyers had not repurchased within 5 years. CephalalgiaFew patients test a second agent: among patients who stopped buying triptans, only 6.2% had tried more than one (4-year no-purchase definition). Cephalalgia In an interview study of 299 triptan-experienced Danish adults, 77% had tried only one type, and 20% recalled being advised to try three if the first failed. Sci RepThe class is also squeezed from both sides: a 137-trial network meta-analysis found eletriptan, rizatriptan, sumatriptan, and zolmitriptan more efficacious than rimegepant and ubrogepant, with confidence in the estimates ranging from high to very low. BMJ The American Headache Society (AHS) consensus statement estimates that about 30% of patients prescribed a triptan respond insufficiently. Headache One of the BMJ investigators, Andrea Cipriani, MD, PhD, professor of psychiatry at the University of Oxford and director of the Oxford Health Clinical Research Facility, Oxford, England, named the gap directly: “there’s no clear consensus among experts and guidelines about which specific drug classes should be prescribed initially, and this is a clinical problem.” MedscapeIf you prescribe these drugs, the questions are which agent, by which route, with or without an NSAID, and when a patient has truly failed the class. The sections below set out seven triptans and two NSAID combination products side by side, with the guideline, trial, and prescribing evidence at each decision point, so you can judge for yourself when to switch agents and when to leave the class.Key data point 1Key data point 2Key data point 312.3%Estimated share of Danish people with migraine who purchased a triptan, 2014 to 2019. Cephalalgia77%Triptan-experienced Danish participants who had tried only one type of triptan. Sci Rep~30%Patients prescribed a triptan who have an insufficient response, per the AHS consensus statement. HeadacheDEEP DIVE:The Triptan Class: Seven Agents, Two NSAID Combinations, and the Art of the SwitchMedscape Medical News © 2026 WebMD, LLCSend comments and news tips to news@medscape.net. Cite this: First-Line but Under-Tested: Choosing Among Seven Triptans, Including Two NSAID Combination Products, for Acute Migraine - Medscape- November 03, 2026.